产品名称
MILLIPLEX® 人癌症/转移生物标志物磁珠板 - 癌症多重检测, Configurable Human Cancer/Metastasis Biomarker 9-Plex Panel
species reactivity
human
manufacturer/tradename
Milliplex®
Quality Level
packaging
1 ea of
assay range
accuracy: 70-105%
standard curve range: 0,019-80 ng/mL
(TRAP5)
standard curve range: 0,048-20 ng/mL
(YKL40)
standard curve range: 0.002-10 ng/mL
(GDF15)
standard curve range: 0.007-30 ng/mL
(DKK-1)
standard curve range: 0.007-30 ng/mL
(OPG)
standard curve range: 0.036-150 ng/mL
(NSE)
standard curve range: 0.195-800 ng/mL
(Periostin)
standard curve range: 0.976-4,00 0 ng/mL
(Osteonectin (SPARC))
inter-assay cv: <16%
intra-assay cv: <10%
technique(s)
multiplexing: suitable
input
serum plasma (Cell culture, cell culture supernatants)
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
Features and Benefits
通过在此面板中选择可用的分析物来设计多重试剂盒。
General description
MILLIPLEX®人类癌症/转移生物标记物面板1包含九种转移生物标志物，这些标志物也已在多种肿瘤类型中得到鉴定。结合珠格式的Luminex® xMAP®平台，该面板使研究人员能够专注于发现，并具有同时定量多重检测的优势，从而提高了速度和灵敏度。
转移是一个复杂的过程，其中肿瘤细胞离开原发肿瘤部位，并通过血液和淋巴管或肿瘤侵袭周围组织和器官而迁移到身体的其他部位。脱离原发肿瘤，癌症细胞附着并降解细胞外基质蛋白，这些蛋白将肿瘤与周围组织分开以逃逸到基质中。转移形成的部位通常取决于原发肿瘤。例如，骨转移往往是由乳腺、前列腺和肾脏肿瘤引起的。这种器官/组织特异性似乎涉及来自趋化因子和生长因子的化学信号。
面板类型：循环癌症
转移是一个复杂的过程，其中肿瘤细胞离开原发肿瘤部位，并通过血液和淋巴管或肿瘤侵袭周围组织和器官而迁移到身体的其他部位。脱离原发肿瘤，癌症细胞附着并降解细胞外基质蛋白，这些蛋白将肿瘤与周围组织分开以逃逸到基质中。转移形成的部位通常取决于原发肿瘤。例如，骨转移往往是由乳腺、前列腺和肾脏肿瘤引起的。这种器官/组织特异性似乎涉及来自趋化因子和生长因子的化学信号。
面板类型：循环癌症
Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 9 analytes in human serum, plasma, tissue/cell culture supernatants or lysate samples.Analytes included: DKK-1, GDF-15, Neuron-specific Enolase (NSE), Osteonectin (SPARC), Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK, YKL40 (CHI3L1)Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Disclaimer
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
法规信息
新产品
此项目有
Paul G Corn et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 990-999 (2020-01-17)
Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa). Patients received ADT plus cabozantinib
R H Brophy et al.
Osteoarthritis and cartilage, 27(12), 1778-1789 (2019-08-21)
Emerging evidence suggests that injury to the anterior cruciate ligament (ACL) typically initiates biological changes that contribute to the development of osteoarthritis (OA). The molecular biomarkers or mediators of these biological events remain unknown. The goal of this exploratory study
Alison Crichton et al.
Journal of neurotrauma, 38(8), 1151-1163 (2019-12-28)
Despite many children experiencing fatigue after childhood brain injury, little is known about the predictors of this complaint. To date, traditional indices of traumatic brain injury (TBI) severity have not predicted reliably persisting fatigue (up to three years post-injury). This
相关内容
Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持